Aurora Health recycling efforts keep almost a ton of trash out of landfills
MILWAUKEE Residents of eastern Wisconsin kept more than 15,000 recyclable and hazardous items out of landfills during Aurora Health Care’s Good Neighbor Day Saturday.
Aurora said Tuesday that items included more than 1,600 pounds of old medication, as well as almost 12,200 pieces of used clothing, more than 600 cell phones, nearly 430 computers and 600 stuffed animals.
Many of the second-hand items went to people in need.
“In every way, the expansion of America Recycles Day into Aurora’s first Good Neighbor Day was a major success,” Aurora senior vice president of corporate affairs Kimberly Welch said in a statement. “It was heart-warming to see so many residents brave this cold day to not only be good environmental stewards, but also help a neighbor in need.”
Donated items also included medical equipment such as walkers and crutches and personal-care items and snacks that will go to women and children undergoing treatment at Aurora’s Sexual Assault Treatment Center.
Amgen, Takeda cancer drug trials stopped after deaths
NEW YORK Several deaths have brought phase 3 clinical trials of a cancer drug by Amgen and Takeda Pharmaceutical to a halt.
The two companies are investigating the drug, motesanib, as an initial treatment for small-cell lung cancer, to be used in conjunction with chemotherapy.
A committee monitoring the 600-patient study found more had died early using the drug than those receiving placebo.
“While we are disappointed in the outcome, it is consistent with data seen with some other anti-VEGF therapies and appears to constitute a class effect of these types of agents,” Amgen executive vice president for research and development Roger Perlmutter said in a statement.
Elan appoints Paya as president
SOUTH SAN FRANCISCO, Calif. Elan Corp. has appointed Carlos Paya as president, the company announced Thursday.
Paya will work from Elan?s South San Francisco, Calif., campus, focusing on leading the company’s scientific, clinical and medical initiatives.
“As an immunologist, a former vice dean of clinical investigation at the Mayo Clinic and as a successful industry executive, Dr. Paya has a unique set of attributes and experiences that perfectly match the opportunities and challenges facing Elan,” said Elan chairman of the board Kyran McLaughlin in a statement.
Paya previously worked at Eli Lilly & Co. as vice president of Lilly Research Labs and global leader of the Diabetes and Endocrine Platform. He had served as an executive at Lilly since 2001. He also worked for six years at the Mayo Clinic as professor of medicine, immunology and pathology, in addition to his position as vice dean.